Adeno-associated virus gene therapy for 21-hydroxylase deficiency
US12195767B2 · kind B2 · utility
0Cited by
12References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 17, 2019 |
| Grant date | Jan 14, 2025 |
| Priority date | — |
| Expiry date | Nov 16, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y114/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are recombinant adeno-associated viral vectors expressing 21-hydroxylase (21OH) protein and related uses for treating 21OH deficiency.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.